The UK ME/CFS Biobank: A Disease-Specific Biobank for Advancing Clinical Research Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
The UK ME/CFS Biobank: A Disease-Specific Biobank for Advancing Clinical Research Into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Lacerda, Eliana M, Mudie, Kathleen, Kingdon, Caroline C et al. · Frontiers in neurology · 2018 · DOI
Quick Summary
Researchers in the UK created a special collection of biological samples (like blood) and health information from 600 people—including those with ME/CFS, people with multiple sclerosis, and healthy volunteers. This resource, called the UK ME/CFS Biobank, was designed to help scientists study ME/CFS more effectively and find reliable ways to diagnose the disease. The biobank is being shared with researchers around the world to speed up discovery.
Why It Matters
ME/CFS lacks validated diagnostic biomarkers and requires coordinated research infrastructure to advance understanding of disease mechanisms. This biobank provides a critical shared resource that accelerates biomedical research and enables collaborative investigations that individual labs cannot conduct alone. By making samples and data accessible to the global research community, the UKMEB democratizes ME/CFS research and increases the likelihood of breakthrough discoveries.
Observed Findings
The UKMEB successfully recruited and retained 600 participants with comprehensive clinical phenotyping and biological sample collection
A longitudinal sub-cohort was established with multiple follow-up assessment time-points to track disease progression
Biological samples and data from the UKMEB have been shared with research teams across Europe, America, and the Middle East
The biobank includes comparison groups (MS patients and healthy controls) to enable disease-specific analysis
Participants with ME/CFS were actively involved in biobank development, design, and governance alongside researchers
Inferred Conclusions
A disease-specific biobank model can serve as effective research infrastructure for facilitating biomarker discovery and validation in ME/CFS
Collaborative, open-access biobanks increase research productivity by enabling international collaboration and reducing duplication of recruitment efforts
Patient involvement in biobank design and governance strengthens research relevance and acceptability to affected communities
International harmonization and integration of disease-specific biobanks remain necessary to maximize scientific value and efficiency
Remaining Questions
What This Study Does Not Prove
This paper describes a biobank infrastructure rather than reporting research findings, so it does not establish what causes ME/CFS, identify specific disease biomarkers, or prove efficacy of any diagnostic test or treatment. The presence of a resource does not in itself prove the validity of any subsequent findings from studies using the biobank. This is an infrastructure paper and should not be interpreted as presenting clinical trial data or mechanistic conclusions about disease pathophysiology.
What biomarkers have been identified or validated using UKMEB samples, and how sensitive and specific are these markers for ME/CFS diagnosis?
How have follow-up assessments in the longitudinal sub-cohort revealed changes in biomarkers or symptoms over time, and do these patterns correlate with disease severity or progression?
What specific barriers to sustainability and international expansion have emerged, and what solutions are most feasible?
How does harmonization with other international ME/CFS biobanks and databanks proceed, and what standards should be adopted?